Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer

Joong Bae Ahn

Status: Unknown

Conditions: Metastatic Colorectal Cancer

Treatments: Drug: FOLFIRI, target agent

Study type: Observational

Funder types: Other

Identifiers

NCT03286738

CTP_401

Details and patient eligibility

About

• Registry
• Multicenter, prospective observational study
• Observe adverse events and efficacy in recruited patients for 3 years under real world settings.

Enrollment: 1,800 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Adult patients at least 19 years of age with metastatic colorectal cancer who are planned to receive Bevacizumab or Cetuximab in combination with FOLFIRI regimen as first-line treatment
2. Patients who will receive irinotecan, a component of FOLFIRI regimen, using Camtop Injection®

Exclusion criteria

1. Patients with conditions in which any study drug is contraindicated per the respective approved label.